Mainz Biomed (NASDAQ:MYNZ) Short Interest Down 21.6% in February

Mainz Biomed (NASDAQ:MYNZ) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 79,700 shares, a drop of 21.6% from the February 13th total of 101,700 shares. Based on an average daily volume of 208,300 shares, the days-to-cover ratio is presently 0.4 days. Currently, 3.8% of the company’s shares are sold short.

Mainz Biomed Stock Down 0.2 %

Mainz Biomed stock traded down $0.01 during trading hours on Wednesday, hitting $4.15. The stock had a trading volume of 46,628 shares, compared to its average volume of 90,366. The stock has a market capitalization of $8.30 million, a P/E ratio of -0.06 and a beta of 0.33. Mainz Biomed has a 12-month low of $3.65 and a 12-month high of $45.20. The stock’s 50-day moving average price is $5.45 and its 200-day moving average price is $7.86.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday, November 25th. Maxim Group began coverage on shares of Mainz Biomed in a research note on Friday, February 14th. They set a “buy” rating and a $14.00 target price on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC acquired a new stake in shares of Mainz Biomed (NASDAQ:MYNZ) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned about 0.92% of Mainz Biomed as of its most recent SEC filing.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.